8-K: Phreesia Kicks Off Fiscal 2026 with Strong Q1 Performance, Significantly Reducing Net Loss and Raising Profit Outlook

Phreesia, Inc. announced robust financial results for its fiscal first quarter ended April 30, 2025, showcasing substantial improvements in profitability and cash flow, leading to an upward revision of its fiscal year 2026 Adjusted EBITDA guidance.

Summary

• Total revenue for the fiscal first quarter ended April 30, 2025, reached $115.9 million, marking a 15% increase year-over-year.
• The company significantly reduced its net loss to $3.9 million in Q1 FY26, a substantial improvement from a net loss of $19.7 million in the same period last year.
• Adjusted EBITDA surged to $20.8 million, up from $4.1 million in the prior year's first quarter.
• Phreesia generated $14.9 million in net cash from operating activities, a significant turnaround from net cash used of $0.7 million in Q1 FY25.
• Free cash flow turned positive at $7.5 million, compared to negative $6.2 million in the year-ago quarter.
• The average number of healthcare services clients (AHSCs) grew by 9% year-over-year to 4,411.
• Total revenue per AHSC increased by 6% year-over-year to $26,283.
• Phreesia maintained its fiscal 2026 revenue outlook in the range of $472 million to $482 million.
• The company raised its fiscal 2026 Adjusted EBITDA outlook to a range of $85 million to $90 million, up from the previous range of $78 million to $88 million.
• Cash and cash equivalents stood at $90.9 million as of April 30, 2025, an increase of $6.7 million from January 31, 2025.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant improvements across key financial metrics including net loss, Adjusted EBITDA, and cash flow, coupled with a raised Adjusted EBITDA outlook for the full fiscal year. Operational growth in clients and revenue per client, along with successful product and compliance initiatives, further reinforce a strong performance.

Positives

• Total revenue increased by a strong 15% year-over-year to $115.9 million.
• Net loss dramatically improved to $3.9 million from $19.7 million in the prior year, indicating enhanced operational efficiency.
• Adjusted EBITDA saw a significant increase to $20.8 million from $4.1 million year-over-year, demonstrating strong profitability growth.
• The company transitioned from net cash used in operating activities to net cash provided, generating $14.9 million.
• Free cash flow turned positive at $7.5 million, a substantial improvement from negative $6.2 million in the previous year.
• Cash and cash equivalents increased to $90.9 million, providing strong liquidity.
• The fiscal 2026 Adjusted EBITDA outlook was raised to $85 million $90 million, reflecting confidence in continued operational leverage and efficiency.
• Growth in Average Healthcare Services Clients (AHSCs) by 9% year-over-year to 4,411, and total revenue per AHSC by 6% to $26,283, indicates successful client acquisition and monetization.
• Phreesia was named to G2's 2025 Best Software Awards in the Best Healthcare Software Products category, based on authentic user reviews.
• The company received two 2025 PM360 Pharma Choice awards for effective patient education campaigns, highlighting product impact and differentiation.
• Successful migration to a new PCI DSS 4.0 compliant cardholder data environment enhances security and reduces audit scope.
• Employee contributions and company match raised over $20,000 for Make-A-Wish Hudson Valley, demonstrating strong corporate social responsibility.

Negatives

• Despite significant improvement, the company still reported a net loss of $3.9 million.
• Payment processing expense as a percentage of payment processing fees revenue increased to 72% in Q1 FY26, up from 68% in Q1 FY25.
• The take rate percentage for payment processing slightly decreased year-over-year from 2.9% to 2.8%.

Risks

• Ability to effectively manage growth and meet growth objectives.
• The competitive environment in which the company operates.
• Ability to comply with covenants in the credit agreement with Capital One.
• Changes in market conditions and receptivity to products and services.
• Ability to develop and release new products, services, and enhancements successfully.
• Ability to maintain the security and availability of the platform.
• Impact of cyberattacks, security incidents, or breaches.
• Changes in laws and regulations applicable to the business model.
• Ability to make accurate predictions about the industry and addressable market.
• Ability to attract, retain, and cross-sell to healthcare services clients.
• Ability to continue to operate effectively with a primarily remote workforce and attract and retain key talent.
• Ability to realize the intended benefits of acquisitions and partnerships.
• Difficulties in integrating acquisitions and investments.
• General market, political, economic, and business conditions, including changes in U.S. presidential administration, tariff and trade issues, and warfare/political/economic instability in Ukraine, the Middle East, India, or elsewhere.

Future Outlook

Phreesia is maintaining its fiscal 2026 revenue outlook in the range of $472 million to $482 million, assuming no additional revenue from future acquisitions. The company has updated and raised its Adjusted EBITDA outlook for fiscal 2026 to a range of $85 million to $90 million, reflecting anticipated continued improvements in operating leverage through efficiency. Phreesia expects AHSCs to reach approximately 4,500 in fiscal 2026 and total revenue per AHSC to increase from fiscal 2025. The company believes its current cash balance and cash generated from normal operations provide sufficient flexibility to achieve its fiscal 2026 outlook, with additional borrowing capacity available for future growth opportunities.

Management Comments

• CEO and Co-Founder Chaim Indig stated, "Our fiscal year 2026 is off to a strong start. I am grateful to our team for their continued commitment to our mission, vision and values. I believe our performance is a reflection of our team truly living our values."
• Chaim Indig also noted, "We believe our first quarter performance reflects both solid execution by our team members and momentum for the new products we introduced last year."

Industry Context

Phreesia operates in the patient activation and healthcare technology sector, providing digital solutions for patient intake, outreach, education, and more. The company's strong Q1 FY26 results, particularly the significant improvements in Adjusted EBITDA and cash flow, suggest effective navigation of the competitive landscape and successful monetization of its growing network of healthcare services clients. The recognition with G2's Best Software Awards and PM360 Pharma Choice awards indicates strong product market fit and industry validation. The estimated $10 billion total addressable market and $200,000 annual revenue opportunity per client highlight substantial untapped potential within the ambulatory and hospital markets, positioning Phreesia for continued growth by driving more value for existing clients and expanding its network.

Comparison to Industry Standards

• Phreesia was named to G2's 2025 Best Software Awards in the Best Healthcare Software Products category, a recognition based on authentic reviews from real users on the world's largest and most trusted software marketplace, reaching 100 million buyers annually.
• The company received a Gold 2025 PM360 Pharma Choice award for a colorectal cancer screening campaign developed in partnership with the Colorectal Cancer Alliance, which drove over 220,000 patient engagements.
• Phreesia also earned a Bronze 2025 PM360 Pharma Choice award for a bilingual campaign targeting Spanish-speaking patients with high cholesterol, which outperformed English-only initiatives by 20% in user engagement and intent.
• Management estimates a total addressable market (TAM) of approximately $10 billion and a target client universe of approximately 50,000 addressable healthcare services clients, implying a total annual revenue opportunity of approximately $200,000 per addressable healthcare services client, which is double their fiscal 2025 total revenue per AHSC, indicating significant growth potential relative to current penetration.

Corporate Governance

Stakeholder Impact

• **Shareholders/Investors**: Positive impact due to strong financial performance, significant reduction in net loss, substantial increase in Adjusted EBITDA, positive cash flow generation, and an upward revision of the fiscal 2026 Adjusted EBITDA outlook, indicating improved profitability and financial health.
• **Healthcare Providers (Clients)**: Positive impact through continued growth in the client network (AHSCs), increased revenue per client, and enhanced product offerings, including improved security with PCI DSS 4.0 compliance and award-winning patient engagement solutions.
• **Patients**: Positive impact through Phreesia's mission to make care easier, enabling approximately 170 million patient visits in 2024, and successful patient education campaigns that drive awareness and promote early detection for critical health conditions.
• **Employees**: Positive impact through management's gratitude for their commitment, focus on employee well-being and company culture (as highlighted in the upcoming Impact Report), and participation in community initiatives like the Make-A-Wish donation.
• **Life Sciences Companies and Other Organizations**: Positive impact as Phreesia's growing network and effective messaging capabilities provide valuable channels for direct communication and engagement with patients.

Next Steps

• Publication of the first Impact Report on the investor relations website on May 30, 2025.
• Filing of the Quarterly Report on Form 10-Q for the fiscal quarter ended April 30, 2025, with the SEC.
• Continued focus on efficiency to drive operating leverage across the company.
• Potential pursuit of future growth opportunities through acquisitions, not currently incorporated into the fiscal 2026 outlook.
• Deployment of cash to profitable growth and value-enhancing opportunities as they arise.

Key Dates

Recommendation

Keywords

Healthcare Technology, Patient Activation, SEC Filing, Financial Results, Q1 Fiscal 2026, Phreesia, PHR, Adjusted EBITDA, Revenue Growth, Cash Flow, Patient Payments, Healthcare Services Clients, Software Awards, PCI DSS Compliance, Digital Health, Patient Engagement, Revenue Cycle Management